JP2016526563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526563A5 JP2016526563A5 JP2016524740A JP2016524740A JP2016526563A5 JP 2016526563 A5 JP2016526563 A5 JP 2016526563A5 JP 2016524740 A JP2016524740 A JP 2016524740A JP 2016524740 A JP2016524740 A JP 2016524740A JP 2016526563 A5 JP2016526563 A5 JP 2016526563A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- independently
- compound
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 halogen anion Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 5
- 206010006451 bronchitis Diseases 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 150000002367 halogens Chemical group 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 230000000172 allergic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 206010001889 Alveolitis Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 230000036428 airway hyperreactivity Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13175552 | 2013-07-08 | ||
| EP13175552.2 | 2013-07-08 | ||
| PCT/EP2014/063947 WO2015003958A1 (en) | 2013-07-08 | 2014-07-01 | Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526563A JP2016526563A (ja) | 2016-09-05 |
| JP2016526563A5 true JP2016526563A5 (https=) | 2017-08-17 |
| JP6449870B2 JP6449870B2 (ja) | 2019-01-09 |
Family
ID=48745847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524740A Active JP6449870B2 (ja) | 2013-07-08 | 2014-07-01 | 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9126982B2 (https=) |
| EP (1) | EP3019492B1 (https=) |
| JP (1) | JP6449870B2 (https=) |
| WO (1) | WO2015003958A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| EP4215244A4 (en) * | 2020-09-15 | 2025-02-26 | Mitsubishi Tanabe Pharma Corporation | Triazine compound salt, crystal form thereof, and production method therefor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE639386A (https=) * | 1962-10-30 | |||
| JP2007502829A (ja) * | 2003-08-18 | 2007-02-15 | パリオン・サイエンシィズ・インコーポレーテッド | 環状ピラジノイルグアニジンナトリウムチャネルブロッカー |
| CA2575680A1 (en) * | 2004-08-18 | 2006-03-02 | Michael R. Johnson | Cyclic amide & ester pyrazinoylguanidine sodium channel blockers |
| GB0526240D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| KR102006612B1 (ko) * | 2011-11-02 | 2019-08-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약제, 이의 용도, 및 이의 제조 방법 |
| US8859559B2 (en) * | 2011-12-20 | 2014-10-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
-
2014
- 2014-07-01 EP EP14735922.8A patent/EP3019492B1/en active Active
- 2014-07-01 WO PCT/EP2014/063947 patent/WO2015003958A1/en not_active Ceased
- 2014-07-01 JP JP2016524740A patent/JP6449870B2/ja active Active
- 2014-07-03 US US14/322,940 patent/US9126982B2/en active Active